Move expands and increases opportunities for studies in both pharmaceutical and nutraceutical industries
Contract research organisation Nutrasource Pharmaceutical and Nutraceutical Services has announced today the rebrand of its clinical trial site.
Headquartered in Southwestern Ontario, Canada, the newly named Apex Trials is a premium clinical trial site, conducting studies in both the pharmaceutical and nutraceutical industries. The primary focus of Apex Trials is Phase I / Pharmacokinetic studies – Phase IV Studies for both Pharmaceutical and Nutraceuticals.
“We are excited to launch our clinical trial site under the brand of Apex Trials,” said Joshua Baisley, SVP Clinical Operations. “We deliberately separated the operations of our site from our CRO activities many years ago to differentiate ourselves from our competitors and demonstrate our commitment to compliance thereby protecting our Sponsor’s investment. With a team of over 20 staff, 20 years of clinical trial experience, and a client-centric approach.”
As a leading clinical trial site, Apex Trials has will focus on both pharmaceutical and nutraceutical studies targeting the following indications:
Apex Trials boasts a 17,000 sqft clinical trial suite under the leadership of Principal Investigator Dr. Anthony Bier. The 20+ site staff includes medical and scientific personnel such as:
Associations represented across a dedicated, certified, and trained team include SOCRA, SCRS, SQA, N2 Network of Networks, and CITI Program.
"Over the past decade, I have been able to witness and appreciate the evolution of our clinical trials unit. I am very proud of the team for accepting and embracing all the physical and procedural changes we have implemented over the years benefiting both our clients and our participants,” said Katie Keene, Clinic Supervisor. “This latest change is our biggest and best yet as it will allow us to expand our focus beyond food and natural health product trials to include pharmaceutical trials, further growing our site’s portfolio of offerings.”